Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Chugai Pharmaceutical Co., Ltd. (4519:JPX), powered by AI.
Chugai Pharmaceutical Co., Ltd. is currently trading at ¥7,428. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Chugai Pharmaceutical Co., Ltd. on Alpha Lenz.
Chugai Pharmaceutical Co., Ltd.'s P/E ratio is 28.2.
“Chugai Pharmaceutical Co., Ltd. trades at a P/E of 28.2 (premium valuation) with strong ROE of 22.1%. Operating margin of 47.6% indicates strong profitability.”
Ask for details →Chugai Pharmaceutical Co., Ltd. is a prominent pharmaceutical company involved in research, development, manufacturing, and marketing of a wide range of pharmaceutical products. Its primary aim is to advance the field of medicine by focusing on the development of innovative therapies that address unmet medical needs. Chugai operates primarily in the fields of oncology, renal disease, and bone and joint diseases, leveraging its capabilities in biotechnology antibody pharmaceuticals. Notably, the company collaborates closely with Roche Group, enabling it to leverage advanced science and technology in drug discovery and development. Chugai's influence is significant in both Japanese and global markets, as it continues to contribute to the enhancement of healthcare by providing high-quality pharmaceutical solutions. Founded in 1925, Chugai is strongly committed to its mission of providing valuable products and services that align with the needs of patients and healthcare providers worldwide.
“Chugai Pharmaceutical Co., Ltd. trades at a P/E of 28.2 (premium valuation) with strong ROE of 22.1%. Operating margin of 47.6% indicates strong profitability.”
Ask for details →Chugai Pharmaceutical Co., Ltd. (ticker: 4519) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - General). It has approximately 5,026 employees. Market cap is $12.2T.
The current price is 7,428 with a P/E ratio of 28.17x and P/B of 6.03x.
ROE is 22.10% and operating margin is 47.60%. Annual revenue is $1.3T.